Curaleaf announces intention to acquire Aurora Cannabis

Curaleaf Holdings announced its intention to launch a takeover bid to acquire all shares of Aurora Cannabis that it does not already control, in a move that could result in the combination of two companies operating internationally in the cannabis market.

The announcement was made by Curaleaf on August 11. Hours later, Aurora Cannabis publicly responded to the initiative, characterizing the potential offer as unsolicited and recommending that its shareholders take no action until a formal proposal is submitted and reviewed.

The transaction does not, therefore, represent a completed acquisition. It concerns Curaleaf's intention to submit an offer, which may be evaluated by Aurora's shareholders and management.

Curaleaf seeks to expand international presence

According to the press release issued by Curaleaf, the company intends to offer Aurora shareholders a combination of cash and Curaleaf shares.

The company argues that an eventual combination would allow for the creation of a cannabis company with greater international scale, bringing together operations in different markets and strengthening its position in the global sector.

The strategy comes at a time of market consolidation, in which companies seek scale, operational efficiency, and presence in regulated markets outside the United States.

Curaleaf operates in the North American market and has an international presence, while Aurora has built a significant presence mainly in the medical cannabis segment and maintains operations in various countries.

Aurora reacts and questions value of potential offer

Aurora's response brought a different perspective on the transaction.

In a press release issued after Curaleaf's announcement, the company stated that it has not received a formal offer and warned its shareholders not to make any decision based solely on the potential buyer's public statement.

Aurora also drew attention to the value indicated by Curaleaf.

According to the company, the upper limit of the consideration presented in the potential transaction is below the price at which its shares traded on December 18, 2025.

The company also highlighted that its board of directors will evaluate any formal proposal if it is actually submitted.

Until that happens, Aurora's guidance is for shareholders to wait.

Offer still needs to be formalized

The difference between an announcement of intent and a formal offer is central to understanding the current stage of negotiations.

Curaleaf informed the market of its intention to launch an acquisition bid, but Aurora itself stressed that, until the publication of its response, no formal proposal had been received.

This means that definitive terms, transaction documentation, and any recommendations from Aurora's board still depend on Curaleaf's next steps.

If the offer moves forward, the transaction could spark a battle over the company's valuation and the support of Aurora's shareholders.

Move highlights industry consolidation

An eventual combination of the companies would expand Curaleaf's scale and combine assets from two companies that built a presence across different regulated cannabis markets.

Curaleaf itself frames the potential acquisition as part of a strategy to solidify its position as one of the leading global companies in the sector.

Aurora, on the other hand, called for caution regarding this narrative and made it clear that any eventual proposal must be analyzed based on its terms and the value offered to shareholders.

For now, therefore, the move should be treated as an unsolicited intention to acquire, and not as a finalized or agreed-upon purchase between the two companies.

Sources: official press releases issued by Curaleaf Holdings and Aurora Cannabis on August 11, 2026.